Paroxetine in the Treatment of Major Depression in Patients with Hematological Malignancy.
- Author:
Chi Un PAE
1
;
Hyek Jae LEE
;
Jung Jin KIM
;
Chang Uk LEE
;
Soo Jung LEE
;
Chul LEE
;
In Ho PAIK
Author Information
1. Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea. knpsy@catholic.ac.kr
- Publication Type:Original Article
- Keywords:
Hematological malignancy;
Major depressive disorder;
Paroxetine;
Open trial
- MeSH:
Depression*;
Depressive Disorder;
Depressive Disorder, Major;
Diagnostic and Statistical Manual of Mental Disorders;
Drug Therapy;
Hematologic Neoplasms*;
Humans;
Nausea;
Paroxetine*
- From:Journal of Korean Neuropsychiatric Association
2003;42(4):485-491
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVES: The efficacy and safety of paroxetine in the treatment of depressive disorders are well known, however its efficacy and safety for the treatment of depression in patients with cancer has been poorly studied. This study therefore aimed to evaluate the efficacy and safety of paroxetine in treatment of depressed patients with hematological malignancy (HM). METHODS: Fifty-two patients with major depressive disorder (MDD) based on DSM-IV criteria along with comorbid HM were allotted to 8 weeks trial with a flexible-dose regime of paroxetine in combination with their chemotherapy or supportive pharmacotherapy. Treatment response was assessed at baseline, week 2, week 4, and week 8 with 17-item Hamilton Rating Scale for Depression (HAM-D17), Montgomery sberg Depression Rating Scale (MADRS), and Clinical Global Impression-severity (CGI-S). Side effects were collected with the reported adverse events and laboratory test throughout the study period. RESULTS: 44.2% of 52 patients completed the eight weeks trial. Scores on the HAM-D17, MADRS, and CGI-s (last observation carried forward, LOCF) at baseline were significantly reduced with mean reduction of 30.5%, 32.8%, and 39.1%, respectively, after 8 weeks treatment with paroxetine. Forty-six patients (88.5%) reported at least one adverse event. The most common adverse event observed in this study was nausea and no serious adverse event was found. CONCLUSION: In this preliminary study, overall results showed paroxetine could be used for the treatment of depressed patients with HM, but more controlled study is needed to confirm the efficacy and safety of paroxetine in this area.
